Tun Kiat Ko - Concepedia

Author

Tun Kiat Ko

National Cancer Centre Singapore

Also Known As

T. K. Ko, T.K. Ko, Tun K. Ko, Tun Kiat Ko

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

National Cancer Centre Singapore Duke-NUS Medical School Singapore General Hospital Duke Medical Center National University of Singapore

About

Tun Kiat Ko is an author at National Cancer Centre Singapore specializing in cell biology, medicine, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	1.3K
2	Cell Biology	6	6	1.3K
3	Health Sciences	2	2	36
4	Natural Sciences	2	2	594
5	Immunology	1	1	19

Tun Kiat Ko

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer King Pan Ng, Axel M. Hillmer, Charles Chuah, Nature Medicine Intrinsic ResistanceTumor BiologyRadiation OncologyMedicineReceptor Tyrosine Kinase	2012	550
The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27 Dvora Ganoth, Gil Bornstein, Tun Kiat Ko, Nature Cell Biology Signal TransductionSignaling PathwayCell DivisionCell RegulationNatural Sciences	2001	467
RUNX3 Is Frequently Inactivated by Dual Mechanisms of Protein Mislocalization and Promoter Hypermethylation in Breast Cancer Quek Choon Lau, Erna Raja, Manuel Salto‐Tellez, Cancer Research	2006	192
CrkRS Tun Kiat Ko, Emma Kelly, Jonathon Pines Journal of Cell Science Systems BiologySignal TransductionProtein FunctionSignaling PathwayRna Polymerase Ii	2001	127
Three Different Binding Sites of Cks1 Are Required for p27-Ubiquitin Ligation Danielle Sitry, Markus A. Seeliger, Tun Kiat Ko, Journal of Biological Chemistry	2002	91
Claudin-1 Has Tumor Suppressive Activity and Is a Direct Target of RUNX3 in Gastric Epithelial Cells Ti Ling Chang, Kosei Ito, Tun Kiat Ko, Gastroenterology Direct TargetMedicinePathologyTumor SuppressorCancer Biology	2009	90
An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia Tun Kiat Ko, Asif Javed, Kian Leong Lee, Blood	2020	66
The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors Tun Kiat Ko, Charles Chuah, King-Pan Ng, Oncotarget	2014	64
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer Shinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, Cancer Science	2019	34
Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches Divya Khosla, Shagun Misra, Pek Lim Chu, Cancers	2024	33

Page 1